Tilman D Rachner1,2,3, Andy Göbel4,5,6, Oliver Hoffmann7, Kati Erdmann8,9,10,11,12, Sabine Kasimir-Bauer7, Dorit Breining1,2,3, Rainer Kimmig7, Lorenz C Hofbauer1,2,3, Ann-Kathrin Bittner7. 1. Division of Endocrinology and Metabolic Bone Diseases, Department of Medicine III, Technische Universität Dresden, Dresden, Germany. 2. Center for Healthy Ageing Department of Medicine III, Technische Universität Dresden, Dresden, Germany. 3. German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Division of Endocrinology and Metabolic Bone Diseases, Department of Medicine III, Technische Universität Dresden, Dresden, Germany. andy.goebel@uniklinikum-dresden.de. 5. Center for Healthy Ageing Department of Medicine III, Technische Universität Dresden, Dresden, Germany. andy.goebel@uniklinikum-dresden.de. 6. German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany. andy.goebel@uniklinikum-dresden.de. 7. Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. 8. Department of Urology, Technische Universität Dresden, Dresden, Germany. 9. National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany. 10. German Cancer Research Center (DKFZ), Heidelberg, Germany. 11. Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 12. Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.
Abstract
PURPOSE: Periostin is a secreted extracellular matrix protein, which was originally described in osteoblasts. It supports osteoblastic differentiation and bone formation and has been implicated in the pathogenesis of several human malignancies, including breast cancer. However, little is known about the prognostic value of serum periostin levels in breast cancer. METHODS: In this study, we analyzed serum levels of periostin in a cohort of 509 primary, non-metastatic breast cancer patients. Disseminated tumor cell (DTC) status was determined using bone marrow aspirates obtained from the anterior iliac crests. Periostin levels were stratified according to several clinical parameters and Pearson correlation analyses were performed. Kaplan-Meier survival curves were assessed by using the log-rank (Mantel-Cox) test. To identify prognostic factors, multivariate Cox regression analyses were used. RESULTS: Mean serum levels of periostin were 505 ± 179 pmol/l. In older patients (> 60 years), periostin serum levels were significantly increased compared to younger patients (540 ± 184 pmol/l vs. 469 ± 167 pmol/l; p < 0.0001) and age was positively correlated with periostin expression (p < 0.0001). When stratifying the cohort according to periostin serum concentrations, the overall and breast cancer-specific mortality were significantly higher in those patients with high serum periostin (above median) compared to those with low periostin during a mean follow-up of 8.5 years (17.7% vs. 11.4% breast cancer-specific death; p = 0.03; hazard ratio 1.65). Periostin was confirmed to be an independent prognostic marker for breast cancer-specific survival (p = 0.017; hazard ratio 1.79). No significant differences in serum periostin were observed when stratifying the patients according to their DTC status. CONCLUSIONS: Our findings emphasize the relevance of periostin in breast cancer and reveal serum periostin as a potential marker for disease prediction, independent on the presence of micrometastases.
PURPOSE:Periostin is a secreted extracellular matrix protein, which was originally described in osteoblasts. It supports osteoblastic differentiation and bone formation and has been implicated in the pathogenesis of several humanmalignancies, including breast cancer. However, little is known about the prognostic value of serum periostin levels in breast cancer. METHODS: In this study, we analyzed serum levels of periostin in a cohort of 509 primary, non-metastatic breast cancerpatients. Disseminated tumor cell (DTC) status was determined using bone marrow aspirates obtained from the anterior iliac crests. Periostin levels were stratified according to several clinical parameters and Pearson correlation analyses were performed. Kaplan-Meier survival curves were assessed by using the log-rank (Mantel-Cox) test. To identify prognostic factors, multivariate Cox regression analyses were used. RESULTS: Mean serum levels of periostin were 505 ± 179 pmol/l. In older patients (> 60 years), periostin serum levels were significantly increased compared to younger patients (540 ± 184 pmol/l vs. 469 ± 167 pmol/l; p < 0.0001) and age was positively correlated with periostin expression (p < 0.0001). When stratifying the cohort according to periostin serum concentrations, the overall and breast cancer-specific mortality were significantly higher in those patients with high serum periostin (above median) compared to those with low periostin during a mean follow-up of 8.5 years (17.7% vs. 11.4% breast cancer-specific death; p = 0.03; hazard ratio 1.65). Periostin was confirmed to be an independent prognostic marker for breast cancer-specific survival (p = 0.017; hazard ratio 1.79). No significant differences in serum periostin were observed when stratifying the patients according to their DTC status. CONCLUSIONS: Our findings emphasize the relevance of periostin in breast cancer and reveal serum periostin as a potential marker for disease prediction, independent on the presence of micrometastases.
Authors: Cédrik Labrèche; David P Cook; John Abou-Hamad; Julia Pascoal; Benjamin R Pryce; Khalid N Al-Zahrani; Luc A Sabourin Journal: Breast Cancer Res Date: 2021-11-22 Impact factor: 6.466
Authors: E Massy; J C Rousseau; M Gueye; E Bonnelye; M Brevet; L Chambard; M Duruisseaux; O Borel; C Roger; R Guelminger; J B Pialat; E Gineyts; L Bouazza; M Millet; J M Maury; P Clézardin; N Girard; Cyrille B Confavreux Journal: J Bone Oncol Date: 2021-06-05 Impact factor: 4.072